PointState Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

PointState Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,000,000	Closed	-$129M	–	173
2017 Q2	$129M	Buy	+1,000,000	New	+$120M	1.4%	24

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

PointState Capital's VRTX Position: Q1 2022 in Review

PointState Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2022, closing a stake of 17,500 shares — an estimated $3.84M sold.

PointState Capital first reported a position in VRTX in Q2 2015 and held it in 15 quarters. The position peaked at $132M in Q2 2018. 1,072 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

PointState Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
PointState Capital sold 17,500 Vertex Pharmaceuticals shares in Q1 2022, an estimated $3.84M.
PointState Capital first reported a position in Vertex Pharmaceuticals in Q2 2015 and held it in 15 quarters.
PointState Capital's Vertex Pharmaceuticals position peaked at $132M in Q2 2018.
1,072 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on PointState Capital's 13F filing for Q1 2022, filed 13 May 2022.